Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW10508 MR pilot study in major depressive disorder
ACTRN12623001080617Phase 2Recruiting
- Sponsor
- XWPharma
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of XW10508 MR in major depressive disorder (MDD) (4 cohorts), sponsored by XWPharma. Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale score from baseline. Started Dec 2023; status: recruiting.
02
Drugs
XW10508 MR
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12623001080617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001080617.